Anthera Pharmaceuticals Operating Income

Anthera Pharmaceuticals (ANTH) currently reports a operating income of $-37M as of March 2018. That compares with $-56M in the prior-year period — up 34.4% year over year. Use the charts on this page to explore Anthera Pharmaceuticals's operating income history and peer comparisons.

Anthera Pharmaceuticals's operating income increased from $-56M to $-37M — a 34.4% year-over-year increase (period ending March 2018). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Anthera Pharmaceuticals reported $-37M in operating income as of March 2018. That compares with $-56M in the prior-year period — up 34.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-37M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Anthera Pharmaceuticals, and consider following ANTH for alerts when major investors trade the stock.

Anthera Pharmaceuticals is classified in the Healthcare sector. On operating income, it currently shows $-37M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ANTH with unrelated industries.